Anebulo Pharmaceuticals AI Stock Analysis
Want to see ANEB full AI Analyst Report?
Anebulo Pharmaceuticals (ANEB) AI Stock Analysis
Anebulo Pharmaceuticals
(Other OTC:ANEB)
ANEB scores near the bottom of the range, driven primarily by severely bearish technicals and weak financial fundamentals. The stock is in a pronounced downtrend, trading at a fraction of its 200-day moving average with oversold but still deteriorating momentum indicators. Financially, the company generates no revenue, burns cash at ~$5.8M annually, and faces an eroding equity base that will likely necessitate dilutive capital raises. The debt-free balance sheet and moderating burn rate provide modest positives, but these are insufficient to offset the lack of revenue, clinical-stage risk, and persistent price deterioration. Valuation offers limited insight given the pre-commercial stage. This is a high-risk, speculative investment entirely dependent on clinical pipeline outcomes and future financing.
Anebulo Pharmaceuticals (ANEB) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $10.60M
- Dividend Yield
- ―
- Average Volume (3M)
- 466
- Price to Earnings (P/E)
- -1.7
- Beta (1Y)
- -116.56
- Revenue Growth
- ―
- EPS Growth
- 33.15%
- Country
- US
- Employees
- 3
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Anebulo Pharmaceuticals Business Overview & Revenue Model
Company Description
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company’s le...
How the Company Makes Money
null
Anebulo Pharmaceuticals Financial Statement Overview
Summary
Anebulo Pharmaceuticals is a pre-revenue clinical-stage biotech with zero revenue, consistent net losses (~$8M TTM), and deeply negative returns on equity. Positives include a debt-free balance sheet and a moderating cash burn rate (operating cash outflow improved to $5.8M TTM from $9.7M in FY2023). However, stockholders' equity has eroded from $21.4M to $7.9M, raising runway concerns. The income statement score of 15, balance sheet score of 45, and cash flow score of 20 collectively reflect a fragile but not immediately critical financial position, contingent on future capital raises and clinical success.
Income Statement
15Very NegativeBalance Sheet
45NeutralCash Flow
20Very Negative| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -7.42M | -7.72M | -7.90M | -11.73M | -6.83M | -30.24M |
| Net Income | -7.98M | -8.48M | -8.20M | -11.73M | -6.83M | -30.25M |
Balance Sheet | ||||||
| Total Assets | 9.42M | 12.15M | 4.07M | 11.67M | 15.58M | 21.65M |
| Cash, Cash Equivalents and Short-Term Investments | 9.04M | 11.63M | 3.09M | 11.25M | 14.55M | 19.99M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.49M | 487.69K | 260.58K | 1.07M | 512.53K | 241.63K |
| Stockholders Equity | 7.94M | 11.66M | 3.81M | 10.60M | 15.07M | 21.41M |
Cash Flow | ||||||
| Free Cash Flow | -5.84M | -6.35M | -8.09M | -9.68M | -5.44M | -4.87M |
| Operating Cash Flow | -5.84M | -6.35M | -8.09M | -9.68M | -5.44M | -4.87M |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | -116.66K | 14.88M | -62.35K | 6.38M | 0 | 21.83M |
Anebulo Pharmaceuticals Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANEB, the sentiment is Negative. The current price of 0.26 is below the 20-day moving average (MA) of 0.27, below the 50-day MA of 0.31, and below the 200-day MA of 0.47, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 42.71 is Neutral, neither overbought nor oversold. The STOCH value of 91.93 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANEB.
Anebulo Pharmaceuticals Risk Analysis
Anebulo Pharmaceuticals disclosed 49 risk factors in its most recent earnings report. Anebulo Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksAnebulo Pharmaceuticals Peers Comparison
Overall Rating
PTN46Neutral
CTXR43Neutral
KALA41Neutral
TPST40Underperform
ANEB33Underperform
PHIO30Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | $10.91M | -1.15 | -115.00% | ― | -46.89% | 55.46% | |
| 43Neutral | $14.48M | -0.25 | -67.15% | ― | ― | 57.48% | |
| 41Neutral | $2.47M | -0.00 | -222.32% | ― | ― | 78.25% | |
| 40Underperform | $6.83M | -0.09 | -3552.74% | ― | ― | 61.31% | |
| 33Underperform | $10.60M | -1.69 | -64.46% | ― | ― | 33.15% | |
| 30Underperform | $8.99M | -0.59 | -101.48% | ― | ― | 43.66% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ANEB | Anebulo Pharmaceuticals, Inc. | 0.26 | -2.04 | -88.70% | |
| PTN | Palatin Technologies, Inc. | 6.13 | -7.68 | -55.62% | |
| TPST | Tempest Therapeutics, Inc. | 0.34 | -4.41 | -92.82% | |
| PHIO | Phio Pharmaceuticals | 0.75 | -0.50 | -39.84% | |
| KALA | Kala Bio, Inc. | 3.83 | -945.67 | -99.60% | |
| CTXR | Citius Pharma | 0.53 | -0.47 | -47.30% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Jul 23, 2026
